TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8299668

Group type: EXPERIMENTAL
Intervention: Topically deposited frusemide (F) 10(-4) M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Topically deposited frusemide (F) 10(-3) M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Topically deposited amiloride (A) 10(-5) M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Topically deposited amiloride (A) 10(-4) M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Topically deposited amiloride (A) 10(-3) M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride (A) 10(-2) M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Topically deposited frusemide (F) and amiloride (A) 10(-3) M
Number of subjects: 7

Group type: COMPARATOR
Intervention: Inhaled frusemide (F)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Inhaled bumetanide (B)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Inhaled salbutamol (S)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Topically deposited bumetanide (B)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Topically deposited salbutamol (S)
Number of subjects: 7
Study: 3333529

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31641769

Group type: EXPERIMENTAL
Intervention: Bedtime hypertension treatment (n=9552)
Number of subjects: 19084

Group type: COMPARATOR
Intervention: Upon awakening hypertension treatment (n=9532)
Number of subjects: 19084
Study: 28758192

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg subcutaneously once every 2 weeks (Q2W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26888985

Group type: EXPERIMENTAL
Intervention: Very early and frequent mobilization, commencing within 24 hours
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2104
Study: 24915873

Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells within the tumour in ER-negative tumours
Number of subjects: 12439

Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells within the stroma in ER-negative tumours
Number of subjects: 12439

Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells within the tumour in ER-positive HER2-positive tumours
Number of subjects: 12439

Group type: EXPERIMENTAL
Intervention: CD8+ tumours in ER-negative disease receiving anthracyclines
Number of subjects: 12439

Group type: COMPARATOR
Intervention: CD8-negative tumours in ER-negative disease receiving anthracyclines
Number of subjects: 12439
Study: 22643725

Group type: EXPERIMENTAL
Intervention: Interferential light therapy with two independent cluster probes (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional light therapy with one active probe (n = 15)
Number of subjects: 30
Study: 20493486

Group type: EXPERIMENTAL
Intervention: R-scope (prototype endoscope with two deflecting working channels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional double-channel endoscope
Number of subjects: 0
Study: 18546536

Group type: EXPERIMENTAL
Intervention: Midazolam combined with fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol combined with fentanyl
Number of subjects: 80
Study: 15752103

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride (TCF-AF) dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available breath freshening (CBF) dentifrice
Number of subjects: 0
Study: 12508047

Group type: EXPERIMENTAL
Intervention: Marginal adaptation evaluation using modified USPHS criteria
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Marginal adaptation evaluation excluding steps with a height greater or less than one standard deviation of the mean
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Marginal height boundary for marginal adaptation
Number of subjects: 435
Study: 10639529

Group type: EXPERIMENTAL
Intervention: 300 mg mexiletine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8628358

Group type: EXPERIMENTAL
Intervention: C1 inhibitor (25 plasma units per kilogram of body weight)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: C1 inhibitor (25 plasma units per kilogram)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1324529

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) products
Number of subjects: 0
Study: 6711955

Group type: COMPARATOR
Intervention: Castrated (group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Castrated with testosterone (group 3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact controls (group 1)
Number of subjects: 18
Study: 30764736

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EVOO supplementation
Number of subjects: 8
Study: 29953547

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) IVR
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tenofovir plus Levonorgestrel (TFV/LNG) IVR
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo IVR
Number of subjects: 51
Study: 26558434

Group type: EXPERIMENTAL
Intervention: Amlodipine oral solution 0.5 mg/mL
Number of subjects: 13

Group type: COMPARATOR
Intervention: Norvasc® 5 mg tablets
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 13
Study: 25011980

Group type: EXPERIMENTAL
Intervention: Systematic and planned GP intervention
Number of subjects: 3245

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 3245
Study: 22127561

Group type: EXPERIMENTAL
Intervention: Isotonic sodium bicarbonate infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo infusion (isotonic saline)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both trials (Isotonic sodium bicarbonate infusion and Placebo infusion)
Number of subjects: 11
Study: 19690833

Group type: EXPERIMENTAL
Intervention: Heel-rise work test
Number of subjects: 78
Study: 17875200

Group type: EXPERIMENTAL
Intervention: Cereal bran flakes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wholemeal oat flakes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn flakes
Number of subjects: 12
Study: 15827359

Group type: EXPERIMENTAL
Intervention: Self videotape feedback
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of expert and self videotape feedback
Number of subjects: 70

Group type: COMPARATOR
Intervention: Expert videotape feedback
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All feedback groups
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonfeedback group
Number of subjects: 70

Group type: COMPARATOR
Intervention: All groups (feedback and nonfeedback)
Number of subjects: 70
Study: 11818106

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg intra-vaginally
Number of subjects: 152
Study: 10211492

Group type: EXPERIMENTAL
Intervention: Bupivacaine injection
Number of subjects: 115
Study: 8550362

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg tid for 7 days
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 2775608

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline tremor power
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Plasma theophylline clearance
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: t1/2 elimination
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Volume of distribution
Number of subjects: 6
Study: 339659

Group type: EXPERIMENTAL
Intervention: Clonidine 75 microgram twice daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clonidine and Placebo (combined analysis)
Number of subjects: 21
Study: 31650795

Group type: EXPERIMENTAL
Intervention: β-caryophyllene (126 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29049901

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aerobic exercise and Resistance training
Number of subjects: 48
Study: 26350688

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard sedation)
Number of subjects: 100
Study: 23685488

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) usage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Visually normal healthy subjects (control group)
Number of subjects: 30
Study: 21831967

Group type: EXPERIMENTAL
Intervention: Multi‐component interactive intervention including Web‐based continuing medical education, performance feedback and quality improvement tools
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 205
Study: 18355137

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with Double‐J stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCNL with nephrostomy tube
Number of subjects: 60
Study: 16854755

Group type: EXPERIMENTAL
Intervention: Zinc/clindamycin gel (Zindaclin 1%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clindamycin lotion (Dalacin T)
Number of subjects: 24
Study: 14747124

Group type: EXPERIMENTAL
Intervention: Filtration of cardiotomy suction blood during cardiopulmonary bypass with a fat removal filter (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control patients without filtration (n=14)
Number of subjects: 28
Study: 11170778

Group type: EXPERIMENTAL
Intervention: Nutrison Packs (2 x 1000 mL triple foil laminated pouches)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ross Ready‐to‐Hang containers (2 x 1000 mL rigid plastic bottles)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Giving sets from both systems
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nutrient containers from both systems
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patient days
Number of subjects: 240
Study: 9333394

Group type: EXPERIMENTAL
Intervention: Perforated plastic cap bandage
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined mull bandage with perforated plastic cap
Number of subjects: 40
Study: 8143833

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg, administered four times daily for patients on inhaled corticosteroids and twice daily for those on bronchodilator alone.
Number of subjects: 719

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 719
Study: 3294350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1446
Study: 31009408

Group type: EXPERIMENTAL
Intervention: Intensive transitional care intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 31134640

Group type: EXPERIMENTAL
Intervention: HMB complex (3 g HMB, 14 g arginine, and 14 g glutamine daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (standard nutrition therapy)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: HMB complex (in subgroup with sequential organ failure assessment scores <10)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (in subgroup with sequential organ failure assessment scores <10)
Number of subjects: 88
Study: 29385590

Group type: EXPERIMENTAL
Intervention: Co-payment for consumer genomic testing (CGT)
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Fully subsidized testing
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: Co-payment condition in online experiment
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Fully-subsidized condition in online experiment
Number of subjects: 2037
Study: 28288041

Group type: EXPERIMENTAL
Intervention: Cervarix
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gardasil
Number of subjects: 27
Study: 26317618

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading and 10 mg maintenance dose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clopidogrel (600 mg reloading and 150 mg maintenance dose)
Number of subjects: 44
Study: 23358847

Group type: EXPERIMENTAL
Intervention: Emergency stenting followed by elective resection (ESER group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total abdominal colectomy and ileorectal anastomosis (TACIR group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both techniques (ESER and TACIR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endoscopic stenting followed by elective resection (ESER group)
Number of subjects: 60
Study: 21173304

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0, then 40 mg every other week starting at week 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 72
Study: 18464971

Group type: EXPERIMENTAL
Intervention: Allowing sutures to be wet and uncovered in the first 48 hours following minor excisions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16537347

Group type: EXPERIMENTAL
Intervention: Free visibility aids (reflective and fluorescent slap wrap, reflective durable sticker, educational material)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control group (no visibility aids provided)
Number of subjects: 377
Study: 12902964

Group type: EXPERIMENTAL
Intervention: Manipulation without traction
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Manipulation with manual traction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Premanipulation radiograph and/or CT scan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Premanipulation plus traction radiograph and/or CT scan
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Postmanipulation radiograph and/or CT scan
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Postmanipulation plus traction radiograph and/or CT scan
Number of subjects: 22
Study: 10988047

Group type: EXPERIMENTAL
Intervention: USPIO ferumoxtran-10 at a dose of 0.8 mg Fe/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: USPIO ferumoxtran-10 at a dose of 1.1 mg Fe/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: USPIO ferumoxtran-10 at a dose of 1.7 mg Fe/kg
Number of subjects: 99
Study: 9526177

Group type: EXPERIMENTAL
Intervention: Healthy adult females during the luteal phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients suffering from premenstrual syndrome or major depression during the luteal phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients suffering from premenstrual syndrome or major depression during the follicular phase
Number of subjects: 0
Study: 7692159

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg/day
Number of subjects: 20
Study: 3095912

Group type: EXPERIMENTAL
Intervention: Low-fat diets
Number of subjects: 9

Group type: COMPARATOR
Intervention: Medium-fat diet
Number of subjects: 9
Study: 30701811

Group type: EXPERIMENTAL
Intervention: Patients with chronic hepatitis C with insulin resistance (HOMA index ≥2.77)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Patients with chronic hepatitis C without insulin resistance (HOMA index <2.77)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CRP indicators
Number of subjects: 205
Study: 26017905

Group type: EXPERIMENTAL
Intervention: Jaimy(®)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Classic needle holder (NH)
Number of subjects: 14
Study: 25697740

Group type: EXPERIMENTAL
Intervention: Frozen sushi
Number of subjects: 240

Group type: COMPARATOR
Intervention: Unfrozen sushi
Number of subjects: 240
Study: 23280545

Group type: EXPERIMENTAL
Intervention: Saffron (30 mg/daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 20625290

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor blockers (MRBs) such as spironolactone or eplerenone, low doses added onto an angiotensin-converting enzyme inhibitor-based regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor blockers (MRBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 18924005

Group type: EXPERIMENTAL
Intervention: aluminum hydroxide‐magnesium hydroxide (Maalox)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: baby shampoo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: milk
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: water
Number of subjects: 49
Study: 16149294

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g three times daily during radiotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo tablets during radiotherapy
Number of subjects: 51
Study: 11975425

Group type: EXPERIMENTAL
Intervention: Remifentanil with 0.5 MAC desflurane (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil with sevoflurane (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Alfentanil with 1 MAC desflurane (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 10515237

Group type: EXPERIMENTAL
Intervention: Serum thrombomodulin (TM) levels in nonsurvivors with DIC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum thrombomodulin (TM) levels in survivors with DIC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrin degradation product (FDP) levels in nonsurvivors with DIC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrin degradation product (FDP) levels in survivors with DIC
Number of subjects: 0
Study: 8521122

Group type: COMPARATOR
Intervention: 12 mM NaF (F)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.55 mM CHX diacetate+F (F‐CHX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mM Zn acetate+F (F‐Zn)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of F‐CHX‐Zn
Number of subjects: 10
Study: 2140488

Group type: EXPERIMENTAL
Intervention: Isoflurane-based anesthetic
Number of subjects: 31

Group type: COMPARATOR
Intervention: Alfentanil continuous infusion
Number of subjects: 31
Study: 6996086

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 30376644

Group type: EXPERIMENTAL
Intervention: Pozik‐Bizi program
Number of subjects: 420

Group type: COMPARATOR
Intervention: Play program
Number of subjects: 420
Study: 27786520

Group type: EXPERIMENTAL
Intervention: Working overtime
Number of subjects: 182

Group type: COMPARATOR
Intervention: Not working overtime
Number of subjects: 182
Study: 26018970

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Heavy slow resistance training (HSR)
Number of subjects: 58
Study: 24838660

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 160
Study: 22954122

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (normal blood pressure patients)
Number of subjects: 57
Study: 18978503

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 2 g/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methadone + Acetyl-L-carnitine (ALC) in morphine-tolerant mice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 17890354

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced coronary CT angiography
Number of subjects: 53
Study: 10728949

Group type: EXPERIMENTAL
Intervention: Highest fibrinogen tertile
Number of subjects: 258

Group type: COMPARATOR
Intervention: First tertile of fibrinogen
Number of subjects: 258

Group type: COMPARATOR
Intervention: Second tertile of fibrinogen
Number of subjects: 258
Study: 9046194

Group type: EXPERIMENTAL
Intervention: Tannic acid (20%) lotion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Iontophoresis
Number of subjects: 10
Study: 1326339

Group type: EXPERIMENTAL
Intervention: ORG 2766 (20 mg per day during 4 weeks)
Number of subjects: 14
Study: 4015388

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Primary closure with subcutaneous drains
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Delayed primary closure
Number of subjects: 105
Study: 30994586

Group type: EXPERIMENTAL
Intervention: 3-exercise pedaling protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-exercise, non-pedaling protocol
Number of subjects: 60
Study: 29892041

Group type: EXPERIMENTAL
Intervention: Vitamin D (4000 IU/d) for 4 months
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 26988951

Group type: EXPERIMENTAL
Intervention: Continued warfarin during surgery
Number of subjects: 659

Group type: COMPARATOR
Intervention: No CSH (control group)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: CSH presence
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Empiric antibiotics upon development of hematoma
Number of subjects: 659
Study: 25590926

Group type: EXPERIMENTAL
Intervention: Magnesium pidolate (MgP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22753635

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Brief education and support condition
Number of subjects: 173
Study: 21092447

Group type: EXPERIMENTAL
Intervention: PAD (bortezomib + adriamycin + dexamethasone)
Number of subjects: 54

Group type: COMPARATOR
Intervention: VAD (vincristine + adriamycin + dexamethasone)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PAD
Number of subjects: 54

Group type: COMPARATOR
Intervention: VAD
Number of subjects: 54

Group type: COMPARATOR
Intervention: PAD and VAD
Number of subjects: 54
Study: 18396717

Group type: EXPERIMENTAL
Intervention: Autologous free fat particle injection
Number of subjects: 41

Group type: COMPARATOR
Intervention: Autologous free fat particle injection combined with bFGF (4,200 IU/10 mL)
Number of subjects: 41
Study: 15810932

Group type: EXPERIMENTAL
Intervention: Information skills training for social-care practitioners and health-care librarians
Number of subjects: 23
Study: 12878632

Group type: EXPERIMENTAL
Intervention: Alizapride 50 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 84